`May 2009 – June 2016
`($ millions)
`
`$180
`
`$160
`
`$140
`
`$120
`
`$100
`
`$80
`
`$60
`
`$40
`
`$20
`
`$0
`
`Source: Ex. 2174, p. 3
`
`Page 1 of 3
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2174 - 1/3
`
`
`
`VIMPAT® U.S. Annual Sales
`May 2009 – June 2016
`($ millions)
`
`2009
`$57.3
`‐$15.8
`$41.5
`
`2010
`$148.4
`‐$22.4
`$126.1
`
`2011
`$265.1
`‐$47.2
`$217.9
`
`2012
`$395.9
`‐$80.0
`$315.9
`
`2013
`$537.7
`‐$130.7
`$407.0
`
`2014
`$720.0
`‐$276.5
`$443.5
`
`2015
`$868.6
`‐$300.3
`$568.3
`
`2016
`$537.8
`‐$216.7
`$321.1
`
`Total
`$3,530.8
`‐$1,089.5
`$2,441.3
`
`Gross Sales
`Deductions
`Net Sales
`
`Source:
`Ex. 2174, p. 3
`
`Page 2 of 3
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2174 - 2/3
`
`
`
`VIMPAT® U.S. Quarterly Sales
`May 2009 – June 2016
`($ millions)
`
`Q2 '09
`$29.0
`‐$3.9
`$25.1
`
`Q1 '13
`$110.1
`‐$24.2
`22%
`$85.9
`
`Q3 '09
`$10.5
`‐$2.6
`$7.9
`
`Q2 '13
`$121.4
`‐$26.7
`22%
`$94.7
`
`Q4 '09
`$17.7
`‐$9.2
`$8.5
`
`Q3 '13
`$145.2
`‐$35.3
`24%
`$109.8
`
`Q1 '10
`$22.8
`‐$1.0
`$21.7
`
`Q4 '13
`$161.0
`‐$44.5
`28%
`$116.5
`
`Q2 '10
`$35.6
`‐$4.4
`$31.2
`
`Q1 '14
`$149.1
`‐$48.8
`33%
`$100.3
`
`Q3 '10
`$41.5
`‐$7.6
`$33.8
`
`Q2 '14
`$167.5
`‐$63.6
`38%
`$103.9
`
`Q4 '10
`$48.7
`‐$9.3
`$39.3
`
`Q3 '14
`$189.2
`‐$79.4
`42%
`$109.8
`
`Q1 '11
`$55.9
`‐$10.5
`$45.4
`
`Q4 '14
`$214.2
`‐$84.7
`40%
`$129.5
`
`Q2 '11
`$60.0
`‐$9.9
`$50.1
`
`Q1 '15
`$180.4
`‐$59.8
`33%
`$120.5
`
`Q3 '11
`$68.4
`‐$11.5
`$56.8
`
`Q2 '15
`$220.3
`‐$70.2
`32%
`$150.1
`
`Q4 '11
`$80.9
`‐$15.3
`$65.6
`
`Q3 '15
`$226.9
`‐$84.0
`37%
`$142.9
`
`Q1 '12
`$89.8
`‐$18.1
`$71.7
`
`Q4 '15
`$241.1
`‐$86.3
`36%
`$154.8
`
`Q2 '12
`$84.8
`‐$17.1
`$67.6
`
`Q1 '16
`$260.8
`‐$101.2
`39%
`$159.6
`
`Q3 '12
`$104.4
`‐$21.1
`$83.3
`
`Q4 '12
`$116.9
`‐$23.6
`$93.3
`
`Q2 '16
`$277.0
`‐$115.5
`42%
`$161.5
`
`Total
`$3,530.8
`‐$1,089.5
`31%
`$2,441.3
`
`Gross Sales
`Deductions
`Net Sales
`
`Gross Sales
`Deductions
`Deductions as % of
`Net Sales
`
`Source:
`Ex. 2175
`
`Page 3 of 3
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2174 - 3/3